Clinical trials: Severe Pneumonia
Hemoglobinopathies, Sickle Cell Disease
ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
Patients with red blood cell disorders (RBCDs), such as Sickle cell disease (SCD) and Thalassemia, are chronic, life-threatening conditions that can become multi-organ complications over time, and are likely at an increased risk…
- Conditions
- Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia, Sickle Beta Thalassemia
- Trial name
- NCT06831799
- Testing
- Non applicable, is a patient registry
- Where
- Spain
- Volunteers
- 684 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Covid19, SARS-CoV Infection
COVID-19 Prophylaxis South Africa (COVER HCW)
This is a randomised, multi-center, open label, adaptive, exploratory trial to assess the efficacy of two different drug regimens in terms of preventing symptomatic COVID-19 disease in healthcare workers at high risk of exposure…
- Trial name
- COVER (NCT04561063)
- Testing
- Nitazoxanide, Sofosbuvir/Daclatasvir
- Where
- 2 sites in South Africa
- Volunteers
- 1,950 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Covid19
Screening of Health-care Workers in an University Hospital for SARS-CoV-2
This is an observational prospective study. The aim is to assess the prevalence of test positivity (swab or serological examination) to Coronavirus Disease-2019 (Covid-19) in relation to the duties and related occupational risk.
- Trial name
- STORM-HCW (NCT04567836)
- Testing
- Investigation of the prevalence of test positivity
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- University of Milano Bicocca
Covid19
Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults
This is a VLP SARS-CoV-2 vaccine study of a vaccine developed in Turkey and manufactured according to Good Manufacturing Practices (GMP) requirements. Preclinical toxicology studies on experimental animals are to be concluded.
- Trial name
- COVID-19 (NCT04818281)
- Testing
- SARS-CoV-2 VLP Vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Ihsan GURSEL, PhD, Prof.
Heart Attack, Cardiac Arrest
Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys
Based on limited published epidemiological data, up to an alarming 1 in 50 surgical inpatients die within 30 postoperative days.
- Conditions
- Heart Attack, Cardiac Arrest, Congestive Heart Failure, Atrial Fibrillation
- Trial name
- SATISFY-SOS (NCT02032030)
- Where
- United States
- Volunteers
- 73,952 people
- Sponsor
- Washington University School of Medicine
Pneumonia, Pneumococcal, Myocardial Ischemia
Myocardial Injury and Severe Pneumococcal Pneumonia
Hypothesis: The "novo" cardiovascular events (CVE)in patients with severe community-acquired pneumonia (CAP) are frequent (17%) and could be associated with both direct pneumococcal myocardial invasion, toxin delivery…
- Trial name
- NEUMOCAR (NCT03058211)
- Testing
- Echocardiography, Cardiac Magnetic resonance
- Where
- Spain
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Alejandro Rodriguez Oviedo , MD
COVID-19 Pneumonia
Bevacizumab in Patients With Severe Covid-19
The novel coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019, which causes epidemic worldwide. Novel coronavirus disease (COVID-19) causes acute lung injury (ALI) and acute respiratory distress…
- Trial name
- BEST (NCT04305106)
- Testing
- Bevacizumab, Standard care
- Where
- China
- Volunteers
- 588 people
- Sponsor
- Qilu Hospital of Shandong University
Covid19
STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent infection with SARS-CoV-2 and no therapeutic agent to treat…
- Trial name
- STOP-COVID19 (NCT04817332)
- Testing
- Brensocatib
- Where
- 16 sites in United Kingdom
- Volunteers
- 406 people
- Sponsor
- University of Dundee
COVID-19
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of VIR-7831 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780281
- Testing
- VIR-7831, Remdesivir
- Where
- 105 sites in United States, Denmark and 6 more
- Volunteers
- 367 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04672564
- Testing
- Carrimycin
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 93 people
- Sponsor
- Shenyang Tonglian Group CO., Ltd
Severe Pneumonia, Hypoxemia
Impact of Pulse Oximetry on Hospital Referral Acceptance in Children Under 5 With Severe Pneumonia
The study assesses and compares the effect of 'pulse oximetry' (PO) used by Lady Health Workers (LHWs) at household level on increasing hospital referral acceptance rates in intervention clusters (district Jamshoro) for 0-59…
- Trial name
- NCT03588377
- Testing
- Pulse Oximetry
- Where
- Pakistan
- Volunteers
- 543 people
- Sponsor
- Aga Khan University
SARS-CoV-2, Coronavirus Infection
Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in…
- Conditions
- SARS-CoV-2, Coronavirus Infection, Asymptomatic Condition, COVID-19
- Trial name
- PEACE (NCT04346667)
- Testing
- Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine
- Where
- 3 sites in Pakistan
- Volunteers
- 125 people
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19, Coronavirus
SPI-1005 Treatment in Severe COVID-19 Patients
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19…
- Conditions
- Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
- Trial name
- NCT04483973
- Testing
- Ebselen
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Mesenchymal Stem Cell, COVID-19 Pneumonia
UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients
The goal of this randomized, controlled, open-labeled interventional clinical trial is to test the efficacy and safety of umbilical cord mesenchymal stem cells (UC-MSCs) in the treatment of severe and critical COVID-19 patients.
- Trial name
- NCT05682586
- Testing
- umbilical cord mesenchymal stem cells, paxlovid
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai East Hospital
Sars-CoV2, Symptomatic Condition
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine…
- Conditions
- Sars-CoV2, Symptomatic Condition, Covid-19
- Trial name
- PRECISE (NCT04351191)
- Testing
- Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine
- Where
- 4 sites in Pakistan
- Volunteers
- 137 people
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
Pneumonia, Viral
Steroid and Anticoagulant Therapy in covid19
As COVID-19 has neither standard treatment protocol nor guidelines, there are many treatment protocols foranti-inflammatory corticosteroids and anti-coagulations for severe COVID-19 pneumonia patients.
- Trial name
- SARS-CoV-2 (NCT05021588)
- Testing
- steroid and anticoagulants according to different protocols.
- Where
- Egypt
- Volunteers
- 123 people
- Sponsor
- Assiut University
Major Depressive Disorder, Recurrent, Unspecified
Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder
Depression is a common, recurrent and disabling disorder. Among patients with a chronic course of the disease, 20 to 30% are resistant to antidepressant medications.
- Trial name
- PRESTHYM (NCT01569711)
- Testing
- Deep brain stimulation of nucleus accumbens
- Where
- 10 sites in France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Treatment Failure, Lethargy
RCT of Efficacy of Amoxicillin Over Ampicillin on Severe Pneumonia
Burden: Pneumonia remains the leading infectious cause of death accounting for 920,000 children under five around the world. This means a loss of over 2,500 child lives every day, or over 100 every hour.
- Conditions
- Treatment Failure, Lethargy, Altered Mental Status, Convulsion, Non-Epileptic
- Trial name
- NCT03369093
- Testing
- Amoxicillin
- Where
- Bangladesh
- Volunteers
- 308 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.